Business
AREV IN NEGOTIATIONS TO ACQUIRE 50% OF LIGHTHOUSE GENOMICS INC. TO STRENGTHEN POSITION FOR NATIONAL AND GLOBAL TRADE IN GENETIC ASSETS, LIGHTHOUSE TASKED WITH DOCUMENTING RARE GENETIC FORMS IN AREV’S
AREV IN NEGOTIATIONS TO ACQUIRE 50% OF LIGHTHOUSE GENOMICS INC. TO STRENGTHEN POSITION FOR NATIONAL AND GLOBAL TRADE IN GENETIC ASSETS, LIGHTHOUSE TASKED WITH DOCUMENTING RARE GENETIC FORMS IN AREV’S.
About this update from Arev Life Sciences Global Corp.
[{"type":"text","content":"AREV BRANDS INTERNATIONAL LTDPress ReleaseAREV in negotiations To ACQUIRE 50% OF LIGHTHOUSE GENOMICS INC. TO Strengthen position for National and global trade in genetic assets, Lighthouse tasked with documenting rare genetic Forms in AREV’s EXTENSIVE genetic catalogue.Vancouver, British Columbia, September 11th, 2019 – AREV Brands International Ltd. (\"AREV\" or the “Company”) (CSE - AREV) is pleased to announce that it is negotiating to acquire 50 per cent of Lighthouse Genomics Inc. Lighthouse will remain an independent operating entity with voting control and an agreement to provide AREV holdings with preferential access to genomic analysis to inform AREV breeding operations with advanced genetic science. AREV, a cannabis integrator, conducts extensive breeding research and development to produce proprietary genetic assets through its holdings in BC Bud Depot. The Lighthouse acquisition complements the Company’s purchase of its largest holding, BC Bud Depot assets, which include a seed bank considered to be a world-class genetic resource, as previously announced September 7, 2018. The strategic investment in Lighthouse Genomics Inc. strengthens AREV’s position as an international leader in cannabis genetic research and breeding.AREV’s programs operated by BC Bud Depot will utilize Lighthouse’s proprietary technologies to accelerate breeding of new genetic assets through oversight of the genetic basis of traits in cannabis. Lighthouse’s industry-leading technologies include the Lighthouse Cannabis Assay™ (LCA), which captures 40,000 single nucleotide polymorphisms (SNPs) selected for high relevance within the cannabis genome. The LCA is considered the most comprehensive SNP genotype array chip for cannabis currently available worldwide. Lighthouse has also produced a proprietary bioinformatics software pipeline to analyze and interpret data produced by LCA genotyping or by Whole Genome Sequencing. These data-capture and analytic technologies provide AREV with an unprecedented opportunity to apply strategic genomic intelligence to producing rare and stable traits in new genetic assets, developed with speed and precision far surpassing conventional plant-breeding practices.Timothy Harvey, CEO of Lighthouse Genomics, stated, “Genetic oversight is an indispensable tool for developing cannabis varieties with production effic...